Epitopea Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
46
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$31M
- Investors
-
15
Epitopea General Information
Description
Developer of transatlantic cancer immunotherapeutics designed to target a novel class of tumor-specific antigens. The company's technology builds on its proprietary approach to identify shared, expressed tumor-specific antigens and develop immunotherapies that are anticipated to kill malignant cells while sparing non-cancerous cells, enabling healthcare providers to cure cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication with minimal side effects and durable benefits.
Contact Information
Website
www.epitopea.comCorporate Office
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
Corporate Office
- Babraham Research Campus
- Cambridge CB22 3AT
- England, United Kingdom
Epitopea Timeline
Epitopea Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Early Stage VC (Series A) | 24-Oct-2024 | $31M | Completed | Generating Revenue | ||
| 5. Grant | 12-Sep-2024 | Completed | Generating Revenue | |||
| 4. Grant | 13-Apr-2023 | Completed | Generating Revenue | |||
| 3. Seed Round | 25-Apr-2022 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Jan-2021 | Completed | Startup | |||
| 1. Accelerator/Incubator | Completed | Startup |
Epitopea Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed Preferred |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Epitopea Comparisons
Industry
Financing
Details
Epitopea Competitors (4)
One of Epitopea’s 4 competitors is Enara Bio, a Venture Capital-Backed company based in Oxford, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Enara Bio | Venture Capital-Backed | Oxford, United Kingdom | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Eleven Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Bicycle Therapeutics | Formerly VC-backed | Cambridge, United Kingdom |
Epitopea Signals
Epitopea Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Investissement Quebec | PE/Buyout | Minority | ||
| IRICoR | Corporation | Minority | ||
| Angel (individual) | Minority | |||
| Meltwind Advisory | Venture Capital | Minority | ||
| Innovate UK | Government |
Epitopea FAQs
-
When was Epitopea founded?
Epitopea was founded in 2021.
-
Where is Epitopea headquartered?
Epitopea is headquartered in Cambridge, United Kingdom.
-
What is the size of Epitopea?
Epitopea has 46 total employees.
-
What industry is Epitopea in?
Epitopea’s primary industry is Drug Discovery.
-
Is Epitopea a private or public company?
Epitopea is a Private company.
-
What is Epitopea’s current revenue?
The current revenue for Epitopea is .
-
How much funding has Epitopea raised over time?
Epitopea has raised $44.4M.
-
Who are Epitopea’s investors?
Investissement Quebec, IRICoR, , Meltwind Advisory, and Innovate UK are 5 of 15 investors who have invested in Epitopea.
-
Who are Epitopea’s competitors?
Enara Bio, Agenus, Eleven Therapeutics, and Bicycle Therapeutics are competitors of Epitopea.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process